RGLS - Regulus Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

RGLS is currently covered by 4 analysts with an average price target of $116.39. This is a potential upside of $108.23 (1326.35%) from yesterday's end of day stock price of $8.16.

Regulus Therapeutics's activity chart (see below) currently has 41 price targets and 57 ratings on display. The stock rating distribution of RGLS is 66.67% BUY and 33.33% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 49.18% with an average time for these price targets to be met of 208.54 days.

Highest price target for RGLS is $11, Lowest price target is $7, average price target is $9.

Most recent stock forecast was given by YANAN ZHU from WELLS FARGO on 30-Apr-2025. First documented stock forecast 27-Feb-2014.

Currently out of the existing stock ratings of RGLS, 6 are a BUY (66.67%), 3 are a HOLD (33.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$9

$0.84 (10.29%)

$6

5 months 30 days ago
(30-Apr-2025)

1/2 (50%)

$1.15 (14.65%)

34

Hold

$11

$2.84 (34.80%)

6 months 1 days ago
(29-Apr-2025)

0/2 (0%)

$3.02 (37.84%)

Hold

$7

$-1.16 (-14.22%)

$8

6 months 1 days ago
(29-Apr-2025)

1/2 (50%)

$-0.98 (-12.28%)

370

Buy

7 months 17 days ago
(13-Mar-2025)

1/7 (14.29%)

$7.86 (367.29%)

255

Buy

$6

$-2.16 (-26.47%)

$240

1 years 7 months 13 days ago
(17-Mar-2024)

1/2 (50%)

$3.64 (154.24%)

408

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is RGLS (Regulus Therapeutics) average time for price targets to be met?

On average it took 208.54 days on average for the stock forecasts to be realized with a an average price target met ratio 49.18

Which analyst has the current highest performing score on RGLS (Regulus Therapeutics) with a proven track record?

ALAN CARR

Which analyst has the most public recommendations on RGLS (Regulus Therapeutics)?

Alan Carr has 6 price targets and 4 ratings on RGLS

Which analyst is the currently most bullish on RGLS (Regulus Therapeutics)?

Matthew Luchini with highest potential upside - $156.24

Which analyst is the currently most reserved on RGLS (Regulus Therapeutics)?

Jim Birchenough with lowest potential downside - -$5.16

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?